ETFMG Treatments Testing and Advancements ETF
 
Schedule of Investments
 
December 31, 2023 (Unaudited)
 
   
COMMON STOCKS - 99.7%
 
Shares
   
Value
 
Canada - 4.4%
       
Biotechnology - 1.1%
           
Arbutus Biopharma Corp.(a)
   
42,518
   
$
106,295
 
XBiotech, Inc.(a)
   
7,717
     
30,868
 
             
137,163
 
Life Sciences Tools & Services - 3.3%
               
AbCellera Biologics, Inc.(a)(b)
   
73,571
     
420,090
 
Total Canada
     
557,253
 
                 
Cayman Islands - 3.6%
         
Biotechnology - 3.6%
               
Zai Lab, Ltd. - ADR(a)(b)
   
16,653
     
455,126
 
                 
France - 0.7%
         
Pharmaceuticals - 0.7%
               
Sanofi - ADR(b)
   
1,869
     
92,945
 
                 
Germany - 5.6%
         
Biotechnology - 5.6%
               
BioNTech SE - ADR(a)(b)
   
6,789
     
716,511
 
                 
Japan - 0.7%
         
Pharmaceuticals - 0.7%
               
Takeda Pharmaceutical Co., Ltd. - ADR(b)
   
6,176
     
88,132
 
                 
Netherlands - 2.1%
         
Biotechnology - 2.1%
               
CureVac NV(a)(b)
   
56,774
     
239,019
 
InflaRx NV(a)(b)
   
14,929
     
24,334
 
             
263,353
 
Total Netherlands
     
263,353
 
                 
United Kingdom - 5.9%
         
Biotechnology - 4.5%
               
Immunocore Holdings PLC - ADR(a)(b)
   
8,619
     
588,851
 
           
$
 
Pharmaceuticals - 1.4%
               
AstraZeneca PLC - ADR
   
1,353
     
91,124
 
GSK PLC - ADR
   
2,428
     
89,982
 
             
181,106
 
Total United Kingdom
     
769,957
 
                 
United States - 76.7%(c)
         
Biotechnology - 44.0%(d)
               
AbbVie, Inc.
   
614
     
95,152
 
Alnylam Pharmaceuticals, Inc.(a)
   
4,052
     
775,592
 
Altimmune, Inc.(a)(b)
   
13,623
     
153,259
 
Arcturus Therapeutics Holdings, Inc.(a)
   
6,775
     
213,616
 
BioCryst Pharmaceuticals, Inc.(a)
   
51,928
     
311,049
 
CEL-SCI Corp.(a)(b)
   
12,672
     
34,468
 
Chimerix, Inc.(a)
   
22,538
     
21,693
 
Cue Biopharma, Inc.(a)
   
11,441
     
30,204
 
Dynavax Technologies Corp.(a)(b)
   
32,773
     
458,167
 
Emergent BioSolutions, Inc.(a)
   
13,135
     
31,524
 
Enanta Pharmaceuticals, Inc.(a)
   
5,339
     
50,240
 
Gilead Sciences, Inc.(b)
   
1,141
     
92,432
 
Gritstone bio, Inc.(a)
   
24,173
     
49,313
 
HilleVax, Inc.(a)
   
12,281
     
197,110
 
Icosavax, Inc.(a)
   
12,700
     
200,152
 
ImmunityBio, Inc.(a)(b)
   
123,495
     
619,945
 
Inovio Pharmaceuticals, Inc.(a)
   
69,214
     
35,299
 
Invivyd, Inc.(a)
   
27,919
     
110,001
 
Moderna, Inc.(a)
   
8,773
     
872,474
 
Novavax, Inc.(a)
   
30,118
     
144,566
 
Ocugen, Inc.(a)
   
65,034
     
37,395
 
Regeneron Pharmaceuticals, Inc.(a)(b)
   
106
     
93,099
 
Renovaro Biosciences, Inc.(a)
   
16,911
     
53,608
 
Vaxart, Inc.(a)(b)
   
38,548
     
22,080
 
Vaxcyte, Inc.(a)
   
8,778
     
551,258
 
Vaxxinity, Inc. - Class A(a)
   
32,136
     
27,316
 
Vir Biotechnology, Inc.(a)
   
34,107
     
343,116
 
             
5,624,128
 
Health Care Equipment & Supplies - 6.5%
               
Abbott Laboratories
   
838
     
92,239
 
Cue Health, Inc.(a)
   
39,206
     
6,371
 
Hologic, Inc.(a)
   
1,226
     
87,598
 
OraSure Technologies, Inc.(a)
   
18,631
     
152,774
 
QuidelOrtho Corp.(a)
   
6,612
     
487,304
 
             
826,286
 
Health Care Providers & Services - 15.1%
               
Enzo Biochem, Inc.(a)
   
12,801
     
17,793
 
Fulgent Genetics, Inc.(a)
   
7,513
     
217,201
 
Laboratory Corp. of America Holdings
   
3,143
     
714,372
 
OPKO Health, Inc.(a)
   
196,003
     
295,965
 
Quest Diagnostics, Inc.
   
4,967
     
684,850
 
             
1,930,181
 
Life Sciences Tools & Services - 5.2%
               
Adaptive Biotechnologies Corp.(a)
   
36,706
     
179,859
 
Gurnet Point Capital, LLC (a)(e)
   
16,557
     
1,325
 
Bio-Rad Laboratories, Inc. - Class A(a)
   
1,490
     
481,107
 
             
662,291
 
Pharmaceuticals - 5.9%
               
AN2 Therapeutics, Inc.(a)
   
7,541
     
154,515
 
Atea Pharmaceuticals, Inc.(a)
   
21,155
     
64,523
 
CorMedix, Inc.(a)(b)
   
13,897
     
52,253
 
Eli Lilly and Co.
   
148
     
86,272
 
Johnson & Johnson
   
565
     
88,558
 
Merck & Co., Inc.
   
853
     
92,994
 
Pfizer, Inc.(b)
   
2,868
     
82,570
 
Scilex Holding Co.(a)
   
16,596
     
33,855
 
SIGA Technologies, Inc.
   
18,025
     
100,940
 
             
756,480
 
Total United States
     
9,799,366
 
TOTAL COMMON STOCKS (Cost $25,723,315)
     
12,742,643
 
                 
SHORT-TERM INVESTMENTS - 30.2%
               
Investments Purchased with Proceeds from Securities Lending - 29.9%
               
Mount Vernon Liquid Assets Portfolio, LLC, 5.61%(f)
   
3,827,986
     
3,827,986
 
                 
Money Market Funds - 0.3%
               
First American Government Obligations Fund - Class X, 5.28%(f)
   
37,876
     
37,876
 
TOTAL SHORT-TERM INVESTMENTS (Cost $3,865,862)
     
3,865,862
 
                 
TOTAL INVESTMENTS - 129.9% (Cost $29,589,177)
     
16,608,505
 
Liabilities in Excess of Other Assets - (29.9)%
     
(3,821,619
)
TOTAL NET ASSETS - 100.0%
         
$
12,786,886
 
                 
Percentages are stated as a percent of net assets.
         

The Global Industry Classification Standard (GICS®) was developed by and/or is the exclusive property of MSCI, Inc. and Standard & Poor’s Financial Services LLC (“S&P”). GICS is a service mark of MSCI, Inc. and S&P and has been licensed for use by U.S. Bank Global Fund Services.

ADR - American Depositary Receipt
PLC - Public Limited Company

(a)
Non-income producing security.
(b)
All or a portion of this security is on loan as of December 31, 2023. The total market value of these securities was $3,626,361 which represented 28.4% of net assets.
(c)
To the extent that the Fund invests a significant portion of its assets in the securities of companies of a single country or region, it is more likely to be impacted by events or conditions affecting the country or region.
(d)
To the extent that the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments that significantly affect those industries or sectors.
(e)
Fair value determined using significant unobservable inputs in accordance with procedures established by and under the supervision of the Adviser, acting as Valuation Designee. These securities represented $1,325 or 0.0% of net assets as of December 31, 2023.
(f)
The rate shown represents the 7-day effective yield as of December 31, 2023.


 ETF Managers Trust

The following is a summary of significant accounting policies consistently followed by ETFMG Prime Junior Silver Miners ETF (“SILJ”), ETFMG Prime Cyber Security ETF (“HACK”), ETFMG Prime Mobile Payments ETF (“IPAY”), ETFMG Travel Tech ETF (“AWAY”), ETFMG Treatments, Testing and Advancements ETF (“GERM”), ETFMG Alternative Harvest U.S. ETF (“MJUS”), ETFMG Alternative Harvest ETF (“MJ”), ETFMG Wedbush ETFMG Video Game Tech ETF (“GAMR”), Wedbush ETFMG Global Cloud Technology ETF (“IVES”), BlueStar Israel Technology ETF (“ITEQ”), Etho Climate Leadership U.S. ETF (“ETHO”) and AI Powered Equity ETF (“AIEQ”)(each a “Fund,” or collectively the “Funds”).
 
Security Valuation. Securities listed on a securities exchange, market or automated quotation system for which quotations are readily available (except for securities traded on NASDAQ), including securities traded over the counter, are valued at the last quoted sale price on the primary exchange or market (foreign or domestic) on which they are traded on the valuation date (or at approximately 4:00 pm Eastern Time if a security’s primary exchange is normally open at that time), or, if there is no such reported sale on the valuation date, at the most recent quoted bid price. For securities traded on NASDAQ, the NASDAQ Official Closing Price will be used.

Securities for which quotations are not readily available are valued at their respective fair values as determined in good faith by ETF Managers Group, LLC (the “Adviser”), using procedures adopted by the Board of Trustees (the “Board”). When a security is “fair valued,” consideration is given to the facts and circumstances relevant to the particular situation, including a review of various factors set forth in the pricing procedures adopted by the Funds’ Board. The use of fair value pricing by a Fund may cause the net asset value of its shares to differ significantly from the net asset value that would be calculated without regard to such considerations. As of December 31, 2023, AIEQ, HACK, AWAY, MJUS, IVES, ITEQ and ETHO did not hold any fair valued securities. As of December 31, 2023, SILJ held three fair valued securities, IPAY, MJ, GERM, and GAMR held one fair valued security.
 
As described above, the Funds utilize various methods to measure the fair value of their investments on a recurring basis. U.S. GAAP establishes a hierarchy that prioritizes inputs to valuation methods. The three levels of inputs are:

Level 1
Unadjusted quoted prices in active markets for identical assets or liabilities that the Funds have the ability to access.
 
Level 2
Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.
 
Level 3
Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available; representing the Funds’ own assumptions about the assumptions a market participant would use in valuing the asset or liability and would be based on the best information available.

The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3.
 
The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety, is determined based on the lowest level input that is significant to the fair value measurement in its entirety.
 
The following is a summary of the inputs used to value the Funds’ investments as of December 31, 2023:

ETFMG Treatments Testing and Advancements ETF
 
   
Level 1
   
Level 2
   
Level 3
   
Total
 
Investments:
                       
  Common Stocks
                       
      Canada
 
$
557,253
   
$
   
$
   
$
557,253
 
      Cayman Islands
   
455,126
     
     
     
455,126
 
      France
   
92,945
     
     
     
92,945
 
      Germany
   
716,511
     
     
     
716,511
 
      Japan
   
88,132
     
     
     
88,132
 
      Netherlands
   
263,353
     
     
     
263,353
 
      United Kingdom
   
769,957
     
     
     
769,957
 
      United States
   
9,798,041
     
     
1,325
     
9,799,366
 
Common Stocks - Total
 
$
12,741,318
   
$
   
$
1,325
   
$
12,742,643
 
  Investments Purchased with Proceeds from Securities Lending(a)
   
     
     
     
3,827,986
 
  Money Market Funds
   
37,876
     
     
     
37,876
 
Total Investments
 
$
12,779,194
   
$
   
$
1,325
   
$
16,608,505
 
                                 
   
Refer to the Schedule of Investments for industry classifications.
 

(a)
Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in the table are intended to permit reconciliation of the fair value hierarchy to the amounts listed in the Schedule of Investments.

Amplify Junior Silver Mi... (AMEX:SILJ)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Amplify Junior Silver Mi... Charts.
Amplify Junior Silver Mi... (AMEX:SILJ)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Amplify Junior Silver Mi... Charts.